CEO Gunilla Osswald talks about the recently approved self-administered subcu formulation of lecanemab, called IQLIK, and updates us on a Parkinson's program that is moving along. Plus, how BioArctic's transferrin based brain transporter technology is different than others, which has resulted in numerous prestigious pharma partnerships.

She describes the transferrin receptor based brain transporter technology, which the company recently signed another new partner...

Gunilla Osswald talks about the global approvals Leqembi has received, she makes the case for a European approval, and talks about what...

Professor Lannfelt recounts the history of researching amyloid beta and explains why he thinks it is vital to target amyloid beta...